Skip to main content

Advertisement

SpringerLink
Log in

Clinical assessment and management of dyslipidemia in patients with chronic kidney disease

  • Review Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) is a common cause of cardiovascular disease (CVD). Several factors contribute to the onset and progression of atherosclerosis and CVD in CKD patients. Most of the cases of coronary heart disease in the general population can be explained by traditional risk factors, whereas non-traditional risk factors, including oxidative stress, anemia, inflammation, malnutrition, vascular calcification, and endothelial dysfunction, have been proposed to play a central role in the pathogenesis of CVD in CKD patients. However, the precise mechanism of CVD initiation in CKD patients remains unclear. Lipid-lowering therapies may decrease proteinuria, and increase or maintain renal function. Because the serum levels of triglyceride-rich lipoproteins are increased in CKD patients, particularly in advanced stages, the serum non-HDL cholesterol level may be a better biomarker of dyslipidemia than the serum LDL cholesterol level in this population. A meta-analysis showed that statin therapy was associated with decreased albuminuria in comparison with a placebo. Moreover, lipid-lowering therapy with statins is effective in reducing the risk of CVD in the early stages of CKD, whereas the benefit of statins in patients with end-stage renal disease may be limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evidence, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1–266.

    Google Scholar 

  2. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al. CKD in the Unites States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S13–20.

    Article  PubMed  CAS  Google Scholar 

  3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  PubMed  CAS  Google Scholar 

  4. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005; 68:228–36.

    Google Scholar 

  5. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.

    Article  PubMed  CAS  Google Scholar 

  6. Van der Zee S, Baber U, Elmariah S, Winston J, Fuster V. Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol. 2009;6:580–9.

    Article  PubMed  Google Scholar 

  7. Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4:672–81.

    Article  PubMed  Google Scholar 

  8. Wang TJ, Gona P, Larson MG, Larson MG, Tofler GH, Levy D, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.

    Article  PubMed  CAS  Google Scholar 

  9. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Fiho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006;47:139–48.

    Article  PubMed  CAS  Google Scholar 

  10. Addabbo F, Mallamaci F, Leonardis D, Tripepi R, Tripepi G, Goliqorsky MS, et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant. 2007;22:3521–6.

    Article  PubMed  CAS  Google Scholar 

  11. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28:958–73.

    Article  PubMed  CAS  Google Scholar 

  12. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–7.

    Article  PubMed  CAS  Google Scholar 

  13. Kronenberg F. Dyslipidemia and nephrotic syndrome: recent advances. J Ren Nutr. 2005;15:195–203.

    Article  PubMed  Google Scholar 

  14. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–61.

    Article  PubMed  CAS  Google Scholar 

  15. Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol. 2009;20:293–9.

    Article  PubMed  CAS  Google Scholar 

  16. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl. 2003; 84:S121–4

  17. Chan DT, Dogra GK, Irish AB, Ooi EM, Barrett PH, Chan DC, et al. Chronic kidney disease delays VLDL apoB-100 particle catabolism: potential role of apo C-III. J Lipid Res. 2009;50:2524–31.

    Article  PubMed  CAS  Google Scholar 

  18. Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW. Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism. 2005;54:821–8.

    Article  PubMed  CAS  Google Scholar 

  19. Liang K, Vaziri ND. Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure. Nephrol Dial Transplant. 1997;12:1381–6.

    Article  PubMed  CAS  Google Scholar 

  20. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 1998;13:2281–7.

    Article  PubMed  CAS  Google Scholar 

  21. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.

    Article  PubMed  CAS  Google Scholar 

  22. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3:144–53.

    Article  PubMed  CAS  Google Scholar 

  23. Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis. 2000;153:263–72.

    Article  PubMed  CAS  Google Scholar 

  24. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573–92.

    PubMed  CAS  Google Scholar 

  25. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:1462–6.

    Article  PubMed  CAS  Google Scholar 

  26. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192–6.

    PubMed  CAS  Google Scholar 

  27. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int. 2003;64:1829–37.

    Article  PubMed  CAS  Google Scholar 

  28. Honda H, Ueda M, Kojima S, Mashiba S, Suzuki H, Hosaka N, et al. Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1021–8.

    Article  PubMed  CAS  Google Scholar 

  29. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet. 2007;370:1829–39.

    Article  PubMed  Google Scholar 

  30. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–82.

    PubMed  CAS  Google Scholar 

  31. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808.

    Article  PubMed  Google Scholar 

  32. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition—need for strict control of risk factors. Intern Med. 2005;44:179–87.

    Article  PubMed  Google Scholar 

  33. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.

    Article  PubMed  Google Scholar 

  34. Shoji T, Masakane I, Watanabe Y, Iseki K. Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. Elevated non-high-density lipoprotein cholesterol (Non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:1112–20.

    Article  PubMed  CAS  Google Scholar 

  35. Kitamura A, Noda H, Nakamura M, Kiyama M, Okada T, Imano H, et al. Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb. 2011;18:454–63.

    Article  PubMed  CAS  Google Scholar 

  36. Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr. 2009;90:407–14.

    Article  PubMed  CAS  Google Scholar 

  37. Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis. 1998;32:834–41.

    Article  PubMed  CAS  Google Scholar 

  38. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–58.

    Article  PubMed  CAS  Google Scholar 

  39. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int. 1993;44:115–9.

    Article  PubMed  CAS  Google Scholar 

  40. Amemiya N, Ogawa T, Otsuka K, Ando Y, Nitta K. Comparison of serum albumin, serum C-reactive protein, and pulse wave velocity as predictors of 4-year mortality of chronic hemodialysis patients. J Atheroscler Thromb. 2011;18:1071–9.

    Article  PubMed  CAS  Google Scholar 

  41. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol. 1996;7:728–36.

    PubMed  CAS  Google Scholar 

  42. Soriano S, Gonzalez L, Martin-Malo A, Rodriguez M, Aljama P. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3–5 patients. Clin Nephrol. 2007;67:352–7.

    PubMed  CAS  Google Scholar 

  43. Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008;28:723–31.

    Article  PubMed  CAS  Google Scholar 

  44. Brunskill NJ. Albumin signals the coming of age of proteinuric nephropathy. J Am Soc Nephrol. 2004;15:504–5.

    Article  PubMed  Google Scholar 

  45. Scheuer H, Gwinner W, Hohbach J, Grone EF, Brandes RP, Malle E, et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol. 2000;78:F63–74.

    Google Scholar 

  46. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290:F262–72.

    Article  PubMed  CAS  Google Scholar 

  47. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.

    Article  PubMed  CAS  Google Scholar 

  48. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a high rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998;9:1482–8.

    PubMed  CAS  Google Scholar 

  49. Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E, et al. Statins and progressive renal disease. Med Res Rev. 2002;22:76–84.

    Article  PubMed  CAS  Google Scholar 

  50. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002;17:798–802.

    Article  PubMed  CAS  Google Scholar 

  51. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes study (CARDS). Am J Kidney Dis. 2009;54:810–9.

    Article  PubMed  CAS  Google Scholar 

  52. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. Pravastatin and cardiovascular disease in moderate chronic kidney disease. Atherosclerosis. 2009;206:512–7.

    Article  PubMed  CAS  Google Scholar 

  53. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atrorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–34.

    Article  PubMed  CAS  Google Scholar 

  54. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–9.

    Article  PubMed  CAS  Google Scholar 

  55. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–16.

    Article  PubMed  CAS  Google Scholar 

  56. Inoue T, Ikeda H, Nakamura T, Abe S, Taguchi I, Kikuchi M, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med. 2011;50:1273–8.

    Article  PubMed  Google Scholar 

  57. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003; 41:1–91.

    Google Scholar 

  58. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–97.

    Google Scholar 

  59. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484–9.

    Article  PubMed  CAS  Google Scholar 

  60. Harris K, Thomas M, Short C, Moore R. Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients. J Nephrol. 2002;15:263–9.

    PubMed  Google Scholar 

  61. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.

    Article  PubMed  CAS  Google Scholar 

  62. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47:385–95.

    Article  PubMed  CAS  Google Scholar 

  63. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104.

    PubMed  CAS  Google Scholar 

  64. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–63.

    Article  PubMed  CAS  Google Scholar 

  65. Lemos PA, Serruys PW, de Feyter P, Mercado NF, Goedhart D, Saia F, et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol. 2005;95:445–51.

    Article  PubMed  CAS  Google Scholar 

  66. Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol. 2007;117:64–74.

    Article  PubMed  Google Scholar 

  67. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–54.

    Article  PubMed  CAS  Google Scholar 

  68. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53:741–50.

    Article  PubMed  CAS  Google Scholar 

  69. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.

    Article  PubMed  CAS  Google Scholar 

  70. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009; 2:CD007784.

  71. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297–304.

    Article  PubMed  CAS  Google Scholar 

  72. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45:119–26.

    Article  PubMed  CAS  Google Scholar 

  73. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis. 2007;50:791–802.

    Article  PubMed  CAS  Google Scholar 

  74. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res. 2004;27:259–66.

    Article  PubMed  CAS  Google Scholar 

  75. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    Article  PubMed  CAS  Google Scholar 

  76. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  PubMed  CAS  Google Scholar 

  77. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  PubMed  CAS  Google Scholar 

  78. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010;61:58–61.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, Kidney Center, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan

    Kosaku Nitta

Authors
  1. Kosaku Nitta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kosaku Nitta.

About this article

Cite this article

Nitta, K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin Exp Nephrol 16, 522–529 (2012). https://doi.org/10.1007/s10157-012-0655-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-012-0655-x

Keywords

Search

Navigation